Shanghai Zhijiang Biotechnology

What Shanghai Zhijiang Biotechnology does

Shanghai Zhijiang Biotechnology Co., Ltd. (上海之江生物科技股份有限公司) is a Shanghai-headquartered, publicly listed molecular diagnostics company (Shanghai Stock Exchange STAR Market, ticker 688317) that develops, manufactures, and sells genetic diagnostic reagents and instruments. Founded in 2005 and IPO'd in 2021, the company has built a catalog of more than 500 reagent products paired with proprietary instrument platforms, serving over 5,000 customers across more than 100 countries with a direct distribution model focused on healthcare and medical institutions performing genetic and molecular diagnostic testing. Its stated mission is to decode life through genes and protect health through technology, and its stated vision is to become a globally influential gene diagnostic technology product supplier. The company became prominent during the COVID-19 pandemic as a major Chinese PCR test kit producer, with the post-pandemic period marked by sharp revenue normalization and an apparent strategic pivot back toward broader non-infectious-disease genetic diagnostics.

The business model centers on selling reagent consumables (the recurring revenue engine) bundled or paired with capital instrument placements at clinical laboratories, hospitals, and diagnostic centers. Go-to-market is direct sales to end customers rather than third-party distribution, which provides margin control and customer intimacy but concentrates commercial execution risk in the internal sales organization. Customer segmentation is vertical (healthcare and medical institutions) rather than horizontal, and pricing is not publicly disclosed, suggesting negotiated enterprise contracts typical of regulated IVD sales in China and international markets. Revenue mechanics are driven by test volume × reagent ASP × installed instrument base, with the COVID-19 cycle having produced a clear boom-bust pattern in 2021-2022 versus 2023-2025. No AI/ML capability, software platform, or data-as-a-service offering is disclosed in the available information, positioning the company as a pure-play reagent-and-instrument IVD manufacturer rather than an AI-native diagnostics player.

Name

Shanghai Zhijiang Biotechnology

Legal name

Shanghai Zhijiang Biotechnology Co., Ltd.

Website

https://liferiver.com.cn

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

251–500 employees

Short description

Shanghai Zhijiang Biotechnology is a publicly listed Chinese molecular diagnostics company (SSE: 688317) that develops, manufactures, and sells over 500 genetic diagnostic reagent products and配套 instruments to more than 5,000 healthcare and medical institution customers across 100+ countries via direct distribution.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)

akta.pro secondary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

Keywords

• Molecular diagnostic reagents
• Genetic testing instruments
• PCR diagnostic kits
• Clinical molecular diagnostics
• In vitro diagnostic products

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Distribution channels1 record

Marketing channels1 record

Core offering

Shanghai Zhijiang Biotechnology engages in the research, development, production, and sales of molecular diagnostic reagents and instruments used for genetic testing. The company has developed over 500 reagent products and complementary diagnostic instruments, serving more than 5,000 customers across 100+ countries for clinical and genetic diagnostic applications.

Product overview

Shanghai Zhijiang Biotechnology (之江生物) operates as a genetic diagnostic product supplier offering a dual-product portfolio consisting of reagent products and instrument products. The company has developed over 500 reagent products and serves more than 5000 customers across 100+ countries. The reagent products and instrument products are designed to work together as an integrated diagnostic solution. The company is listed on the Shanghai Stock Exchange (stock code: 688317) and was founded in 2005.

Differentiator

Problem solved

Functional benefit

Products and services

• Reagent Products (试剂产品) A catalog of over 500 diagnostic reagent products used for genetic testing and molecular diagnostics, including PCR-based reagents. These are designed for clinical laboratories, hospitals, and medical institutions performing molecular diagnostic testing.
• Instrument Products (仪器产品) Diagnostic instrument products designed to operate with the company's reagent products to deliver integrated genetic testing solutions. Targeted at clinical laboratories, hospitals, and medical research institutions performing molecular diagnostic testing.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Sansure Biotech: Sansure Biotech is a leading Chinese molecular diagnostics company (688289.SH) developing nucleic acid diagnostic reagents and instruments. It directly competes with Zhijiang in PCR and molecular diagnostic reagent kits for infectious disease and genetic testing in China and internationally.
• BGI Genomics: BGI Genomics (300676.SZ) is one of China's largest genetic testing and molecular diagnostics companies, offering reagents, instruments, and sequencing-based services. It is highly comparable as a Chinese-headquartered IVD reagent and instrument supplier with significant international reach.
• Daan Gene: Daan Gene (002030.SZ) is a Chinese molecular diagnostics and IVD reagent manufacturer with a strong portfolio of PCR-based diagnostic kits. It competes directly with Zhijiang in the Chinese clinical molecular diagnostics market.
• Autobio Diagnostics: Autobio Diagnostics (603658.SH) is a major Chinese IVD company producing diagnostic reagents and instruments across immunoassay, microbiology, and molecular categories. It is a broad incumbent competitor with overlapping reagent manufacturing capabilities.
• Hybio Pharmaceutical: Hybio Pharmaceutical is a Chinese peptide-based therapeutics and diagnostics company with overlapping molecular reagent capabilities. It represents a regional peer with comparable reagent technology exposure.

Regional players

• Kingmed Diagnostics: Kingmed Diagnostics (603882.SH) is one of China's largest third-party medical laboratory networks, providing genetic and molecular diagnostic testing services. While it is a service provider rather than a reagent manufacturer, it is a major downstream customer and adjacent peer in China's genetic diagnostics value chain.

Broad incumbents

• Cepheid (Danaher): Cepheid, owned by Danaher, is a global leader in molecular diagnostic testing systems (GeneXpert) with an integrated reagent-instrument business model directly analogous to Zhijiang's product approach.
• Hologic: Hologic (HOLX) is a global diagnostics and women's health company with a strong molecular diagnostics franchise (Panther system, Aptima assays), competing globally with Zhijiang in molecular diagnostic reagent and instrument markets.
• Qiagen: Qiagen (QGEN) is a global molecular diagnostics and sample-preparation technology leader with a broad reagent and instrument portfolio, including PCR and genomic testing solutions overlapping Zhijiang's offering.
• bioMérieux: bioMérieux is a global IVD company with strong molecular diagnostics and microbiology reagent offerings (e.g., BioFire FilmArray), competing with Zhijiang's reagent and instrument portfolio in international markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shanghai Zhijiang Biotechnology